Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lamivudine/Zidovudine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Lamivudine/Zidovudine | DRUG | - |
| Nelfinavir mesylate | DRUG | - |
| Stavudine | DRUG | - |
| Didanosine | DRUG | - |
Inclusion Criteria Patients may be eligible for this study if they: * Are HIV-positive. * Have a viral load of at least 2,000 copies/ml and a CD4 count of at least 200 cells/mm3. * Are at least 18 years old. * Agree to practice sexual abstinence or to use effective barrier methods of birth control...
Top 20 of 28 competitors
Lamivudine/Zidovudine is a fixed-dose combination of two antiretroviral drugs used for the treatment of HIV Infections. It is being developed by Bristol-Myers Squibb Company and is currently in Phase 3 clinical development. The drug is a small molecule intended to suppress HIV replication and improve patient outcomes.
Lamivudine/Zidovudine targets HIV by combining two nucleoside reverse transcriptase inhibitors. Lamivudine and zidovudine both inhibit the HIV reverse transcriptase enzyme, which is essential for viral replication. By blocking this enzyme, the combination helps reduce the viral load in patients with HIV Infections.
Lamivudine/Zidovudine is developed by Bristol-Myers Squibb Company, a global biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and efficacy of this combination therapy for HIV Infections.
Lamivudine/Zidovudine is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial, NCT00002429, has been completed, and the results will inform potential regulatory submissions for the treatment of HIV Infections.
Lamivudine/Zidovudine has one completed Phase 3 clinical trial, NCT00002429, titled 'Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen.' The trial enrolled 500 participants with HIV Infections in the United States and Canada.
Lamivudine/Zidovudine is a combination of lamivudine and zidovudine, which are also marketed under the brand name Combivir. However, the specific formulation being studied by Bristol-Myers Squibb in the Phase 3 trial may differ from the commercially available product. The trial evaluates this combination as part of an investigational regimen.